Floatz logo

Prax-562

SCN2A Encephalopathy

Praxis Precision MedicinesPhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the SCN2A Encephalopathy cohort.

Asset / SponsorPhaseRating
Elsunersen
Praxis Precision Medicines
Phase 3B

Same molecule, other indications

Prax-562 is also rated in:

developmental and epileptic encephalopathy, 13Dormant
NR
Indicative ·
/ 100
View asset →
developmental and epileptic encephalopathy, 1Dormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →